RC48 was capable of significantly inhibiting the proliferation of HER2-positive GC cells in a dose-dependent manner and exhibited potent antitumor activity in a trastuzumab-resistant xenograft tumor model. This evidence concerns the gene ERBB2 and neoplasm.